Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position

Chinese Patent Approved Covering HT-KIT Technology Designed to Induce Cancer Cell Apoptosis, Expanding Protection in One of the World’s Largest Oncology Markets

NEW YORK, Jan. 21, 2026 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapeutics, today announced that the China National Intellectual Property Administration has approved issuance of a key patent covering the Company’s HT-KIT cancer program, a novel therapeutic approach designed to induce apoptosis in disease-driving cells by targeting KIT signaling pathways.

The patent, which originated from a PCT international application, provides important intellectual property protection in China, one of the world’s largest and fastest-growing oncology markets, and further strengthens Hoth’s global IP estate surrounding HT-KIT.

“This patent issuance represents a significant validation of the HT-KIT platform and materially strengthens our international intellectual property position,” said Robb Knie, Chief Executive Officer of Hoth Therapeutics. “Securing protection in China enhances the long-term strategic and commercial value of HT-KIT as we continue advancing this program as a differentiated cancer-fighting approach.”

HT-KIT: Targeting Cancer Through Apoptosis Pathways

HT-KIT is designed to disrupt aberrant KIT-driven signaling, a pathway implicated in multiple cancers, by leveraging splice-switching and molecular targeting strategies aimed at triggering programmed cell death (apoptosis). This mechanism is intended to selectively impact disease-relevant cells while avoiding broader systemic toxicity associated with traditional cytotoxic therapies.

The newly approved patent covers systems and methods for targeting KIT to induce apoptosis, reinforcing Hoth’s strategy of developing precision oncology therapeutics backed by strong, defensible intellectual property.

Strategic Importance of China IP Coverage

China represents a critical jurisdiction for oncology intellectual property, given its expanding biopharmaceutical market, increasing oncology drug adoption, and growing role in global licensing and partnership activity. Patent protection in China may enhance future partnering, licensing, and strategic transaction opportunities related to HT-KIT.

With this issuance, Hoth continues to convert its international patent filings into issued assets, a key value inflection point often closely followed by biotech investors.

Building a Global Oncology IP Portfolio

The HT-KIT patent adds to Hoth’s expanding portfolio of oncology and immunology assets and underscores the Company’s commitment to building long-duration shareholder value through IP-driven drug development.

Hoth expects to continue advancing HT-KIT while pursuing additional regulatory, development, and strategic milestones across its pipeline.

About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .

Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth’s current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth’s business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management’s expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled “Risk Factors” in Hoth’s most recent Annual Report on Form 10-K and Hoth’s other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth’s current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

Investor Contact:
LR Advisors LLC
Email: [email protected]
www.hoththerapeutics.com
Phone: (678) 570-6791

View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-secures-major-international-patent-milestone-for-ht-kit-cancer-program-strengthening-global-oncology-ip-position-302666244.html

SOURCE Hoth Therapeutics, Inc.